In recent years, the debilitating experience of fatigue in Parkinson’s disease (PD) has emerged as a critical yet often underappreciated symptom impacting patients’ quality of life. Whereas motor impairments such as tremor and rigidity have long occupied the spotlight, non-motor symptoms like fatigue represent a complex clinical challenge. A groundbreaking study led by Yang, Shen, Sun, and colleagues, published in npj Parkinson’s Disease in 2025, presents a pioneering exploration into the neural and molecular mechanisms that underpin fatigue in PD. This research offers the scientific community an unprecedented map linking neural circuitry disruption and molecular pathophysiology in fatigue, potentially opening avenues for targeted therapeutic interventions.
Fatigue in Parkinson’s disease remains a nebulous symptom, described by patients as an overwhelming sense of tiredness not necessarily correlated with physical exertion or sleep quality. Despite its prevalence, which affects over half of PD patients, the precise biological basis of fatigue has eluded researchers due to the complexity of the symptom and the heterogeneity of Parkinsonian pathology. The study by Yang et al. breaks new ground by integrating multi-modal analysis—from neuroimaging to transcriptomics—to dissect the origins of fatigue at multiple biological levels.
The researchers employed advanced brain imaging techniques to identify distinct alterations in neural networks implicated in fatigue among PD patients. Using functional MRI, they observed disrupted connectivity patterns in brain regions integral to arousal regulation and energy metabolism, particularly within the basal ganglia circuitry and prefrontal cortex. This neural disconnection could underlie the impaired ability to sustain motor and cognitive effort, manifesting as the profound fatigue experienced clinically. These imaging findings represent a significant stride by linking structural and functional changes in fatigue, an area previously characterized by more anecdotal clinical observations than empirical data.
Beyond neural circuitry, the team delved into the molecular landscape by analyzing gene expression profiles in peripheral blood mononuclear cells collected from fatigued versus non-fatigued PD patients. They discovered differential regulation of key genes related to mitochondrial function, oxidative stress responses, and neuroinflammation. Notably, the downregulation of mitochondrial biogenesis pathways suggests that impaired cellular energy production may contribute substantially to fatigue. Concurrently, upregulated pro-inflammatory cytokine genes indicate an activated immune state that could exacerbate neuronal dysfunction responsible for the sensation of exhaustion.
This dual focus on brain network disturbances and molecular signatures provides compelling evidence that fatigue in PD is a multi-dimensional phenomenon. The convergence of neuroimaging and transcriptomic data points to a model where disrupted communication within energetically demanding neural circuits couples with systemic biochemical dysregulation to produce the intractable fatigue reported by patients. This integrative approach transcends the traditional symptomatic treatment model by illuminating root causative processes amenable to novel therapies.
One of the most striking revelations of the study is the involvement of the dopaminergic system—not only in motor symptoms but also in fatigue modulation. Dopamine depletion, a hallmark of PD, is already known to impair motivation and motor control, but Yang et al. demonstrate that dopamine deficit also compromises neural substrates governing sustained attention and effort. This mechanistic insight clarifies why dopamine replacement therapies, though improving motor deficits, may insufficiently address fatigue, thereby prompting a reassessment of treatment paradigms.
Moreover, the immune system emerges as a critical player in the fatigue landscape through the identification of inflammatory molecular signatures. This finding aligns with growing evidence from other neurological disorders where chronic neuroinflammation contributes to fatigue’s persistence. The study suggests that targeting systemic inflammation could represent an innovative therapeutic strategy, potentially ameliorating fatigue and improving overall patient outcomes.
In delineating the mitochondrial dysfunction pathway, the researchers highlight bioenergetic failure as a fundamental cause of fatigue. Given mitochondria’s pivotal role in ATP production, their impaired function could lead to reduced neuronal and systemic energy availability. This new understanding aligns with the clinical profile of PD fatigue patients who often describe their exhaustion as pervasive and resistant to rest, consistent with a metabolic energy deficit rather than simple tiredness.
The implications of this research extend to biomarker development. By establishing specific neurobiological and molecular correlates of fatigue in PD, the study lays the groundwork for objective diagnostic tools that can identify fatigue severity and track therapeutic responses. The identification of blood-based gene expression biomarkers offers a minimally invasive means to monitor disease progression and efficacy of emerging treatments aimed at alleviating fatigue.
Crucially, these findings bear the promise of personalized medicine approaches in Parkinson’s disease care. Recognizing fatigue’s multifaceted etiology suggests tailoring treatment regimens based on individual patient profiles—such as degree of mitochondrial impairment or inflammatory marker expression—could optimize symptom control. This precision medicine outlook represents a paradigm shift from the conventional “one-size-fits-all” treatment strategy.
The methodology employed by Yang and colleagues exemplifies the power of integrating diverse scientific disciplines—neuroimaging, genomics, and clinical neurology—to unravel complex pathological mechanisms. Their comprehensive multimodal analysis underscores the necessity of cross-disciplinary approaches in addressing intricate neurodegenerative symptoms, inspiring future research directions to similarly combine cutting-edge technologies.
While the study provides critical insights, it also raises important questions warranting further investigation. For instance, the temporal dynamics of fatigue onset in relation to neurodegeneration remain unclear. Longitudinal studies are needed to determine whether molecular and neural abnormalities precede clinical fatigue or evolve concomitantly, which could inform early intervention strategies.
Additionally, exploring how other neurotransmitter systems, such as serotonergic and noradrenergic pathways, interact with dopaminergic circuits in fatigue generation could yield a more complete picture of the neurochemical basis of this symptom. Such explorations might unlock additional therapeutic targets beyond dopamine-centric treatments.
The researchers also recognize that fatigue’s subjective nature complicates clinical evaluation. Developing standardized, sensitive fatigue rating scales aligned with biological markers will enhance diagnosis and patient monitoring. Combining patient-reported outcomes with objective data could enrich understanding and improve symptom management.
Importantly, this study advances the broader field of neurodegenerative disease research by illustrating how non-motor symptoms, once neglected, can be systematically dissected at molecular and systems levels. Fatigue in Parkinson’s disease thus serves as a model for investigating similar unexplained symptoms in other disorders such as multiple sclerosis and chronic fatigue syndrome, potentially benefiting a wider patient population.
In conclusion, the work of Yang, Shen, Sun, and colleagues marks a significant leap in Parkinson’s disease research by mapping the intertwined neural and molecular mechanisms underpinning fatigue. Their findings not only deepen our comprehension of this debilitating symptom but also chart a course toward innovative diagnostics and personalized treatments. As Parkinson’s disease management evolves, addressing fatigue with mechanistic precision promises to enhance patient quality of life and redefine therapeutic standards.
Subject of Research: Neural and Molecular Mechanisms Underlying Fatigue in Parkinson’s Disease
Article Title: Mapping the Neural and Molecular Basis Underlying Fatigue in Parkinson’s Disease
Article References:
Yang, F., Shen, J., Sun, Z. et al. Mapping the neural and molecular basis underlying fatigue in Parkinson’s disease.
npj Parkinsons Dis. (2025). https://doi.org/10.1038/s41531-025-01216-4
Image Credits: AI Generated
